Solara Active Pharma Sciences (NSE:SOLARA) LT-Debt-to-Total-Asset : 0.04 (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Solara Active Pharma Sciences LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Solara Active Pharma Sciences's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.04.

Solara Active Pharma Sciences's long-term debt to total assets ratio declined from Sep. 2023 (0.07) to Sep. 2024 (0.04). It may suggest that Solara Active Pharma Sciences is progressively becoming less dependent on debt to grow their business.

Solara Active Pharma Sciences LT-Debt-to-Total-Asset Historical Data

The historical data trend for Solara Active Pharma Sciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solara Active Pharma Sciences LT-Debt-to-Total-Asset Chart

Solara Active Pharma Sciences Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.11

0.06

0.10

0.09

0.05

Solara Active Pharma Sciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.07	-	0.05	-	0.04

Solara Active Pharma Sciences LT-Debt-to-Total-Asset Calculation

Solara Active Pharma Sciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (A: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2024 )	/	Total Assets (A: Mar. 2024 )
	=	1174.4	/	23509.6
	=	0.05

Solara Active Pharma Sciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	973.2	/	22897.8
	=	0.04

Solara Active Pharma Sciences (NSE:SOLARA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Solara Active Pharma Sciences LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Solara Active Pharma Sciences's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Solara Active Pharma Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Solara Active Pharma Sciences Ltd (NSE:SOLARA) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

SOLARAPP:India 890202:India 541540:India

Address

27, Vandaloor Kelambakkam Road, 2nd Floor. Admin Block, Melakottaiyur (Post), Keelakottaiyur Village, Chennai, TN, IND, 600 127

Website

https://www.solara.co.in

Solara Active Pharma Sciences Ltd is engaged in Active Pharmaceutical Ingredients manufacturer (API) in India. It manufactures and develops APIs and offers services, including CRAMS and contract manufacturing for APIs. The company offers products and services, such as Anaesthetic, Analgesics, Antiviral, Retinod, Anti-emetic, Antimalarial, Diuretic, Muscle relaxant, Antiallergics, Antihypertensive, Calcimimetic agent, Anti-seizure, Antigout, Cardiovascular, Anti-infective, Cough suppressant and others. It also offers contract services including contract development and manufacturing, analytical services. The group has a business presence in the Asia Pacific, Europe, North America, South America, and other places, of which the majority of income is generated from the Asia Pacific countries.

Solara Active Pharma Sciences Headlines

No Headlines